Comparison of Clinical Outcomes of Intravitreal Ranibizumab and Aflibercept Treatment for Retinopathy of Prematurity

Overview

Journal Graefes Arch Clin Exp Ophthalmol

Specialty Ophthalmology

Date 2018 Nov 7

PMID 30397793

Citations 22

Authors

Emine Alyamac Sukgen

Yusuf Kocluk

Affiliations

Soon will be listed here.

Abstract

Purpose: To compare the results of ranibizumab and aflibercept treatment in infants with treatment-requiring retinopathy of prematurity (ROP) in the posterior zone.

Methods: In this single-center, retrospective study, the records of the infants, who were treated between January 2015 and June 2017 in a tertiary center for screening and treatment of ROP, were reviewed. Infants who were administered ranibizumab or aflibercept as initial treatment and completed at least 1 year of corrected age were included. The patients were evaluated in terms of regression, progression or recurrence of the disease, vascularization of the peripheral retina, and ocular complication profile in early or late period.

Results: Fifty-four eyes of 27 infants who received ranibizumab treatment (ranibizumab group) and 72 eyes of 36 infants who received aflibercept treatment (aflibercept group) were enrolled. The rate of recurrence was 48.1% in ranibizumab group and 13.9% in aflibercept group. The mean recurrence times were at 8.2 ± 0.92 weeks following the injection of ranibizumab and at 14.2 ± 1.03 weeks following the injection of aflibercept. There were significant statistical differences between the groups in the rate of ROP recurrence, the time of recurrence, and the time of vascularization of peripheral retina (p = 0.001, p < 0.001, p < 0.001, respectively).

Conclusion: Although both ranibizumab and aflibercept are effective therapies for the treatment of ROP, more frequent and much earlier recurrences can be seen with ranibizumab treatment. Further studies are needed to obtain ideal options for the treatment of ROP.

Citing Articles

A review on retinopathy of prematurity.

Rashidian P, Karami S, Salehi S Med Hypothesis Discov Innov Ophthalmol. 2025; 13(4):201-212.

PMID: 40065804 PMC: 11890260. DOI: 10.51329/mehdiophthal1511.

A comparation of three different anti-VEGF drugs in development of persistent avascular retina in premature children.

Unal A, Akidan M, Erol M Sci Rep. 2024; 14(1):31097.

PMID: 39732747 PMC: 11682188. DOI: 10.1038/s41598-024-82445-0.

Recurrence of Retinopathy of Prematurity Following Anti-vascular Endothelial Growth Factor (Anti-VEGF) Therapy: A Systematic Review and Meta-Analysis.

Dablouk M, Chhabra A, Masoud A Cureus. 2024; 16(11):e73286.

PMID: 39524166 PMC: 11550109. DOI: 10.7759/cureus.73286.

Efficacy of four anti-vascular endothelial growth factor agents and laser treatment for retinopathy of prematurity: A network meta-analysis.

Xu Y, Deng G, Zhang J, Zhu J, Liu Z, Xu F Biomol Biomed. 2023; 24(4):676-687.

PMID: 37976345 PMC: 11293245. DOI: 10.17305/bb.2023.9829.

The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis.

Chen J, Hao Q, Zhang J, Du Y, Chen H, Cheng X Ital J Pediatr. 2023; 49(1):136.

PMID: 37814332 PMC: 10561404. DOI: 10.1186/s13052-023-01543-3.

References

Sondell M, Lundborg G, Kanje M . Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci. 1999; 19(14):5731-40. PMC: 6783109. View

Jin K, Mao X, Greenberg D . Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci U S A. 2000; 97(18):10242-7. PMC: 27841. DOI: 10.1073/pnas.97.18.10242. View

Good W . Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2005; 102:233-48. PMC: 1280104. View

. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005; 123(7):991-9. DOI: 10.1001/archopht.123.7.991. View

Ferrara N, Damico L, Shams N, Lowman H, Kim R . Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006; 26(8):859-70. DOI: 10.1097/01.iae.0000242842.14624.e7. View

Warden S, Andreoli C, Mukai S . The Wnt signaling pathway in familial exudative vitreoretinopathy and Norrie disease. Semin Ophthalmol. 2007; 22(4):211-7. DOI: 10.1080/08820530701745124. View

Saint-Geniez M, Maharaj A, Walshe T, Tucker B, Sekiyama E, Kurihara T . Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS One. 2008; 3(11):e3554. PMC: 2571983. DOI: 10.1371/journal.pone.0003554. View

Gilbert C, Muhit M . Twenty years of childhood blindness: what have we learnt?. Community Eye Health. 2008; 21(67):46-7. PMC: 2580065. View

Mintz-Hittner H, Kennedy K, Chuang A . Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011; 364(7):603-15. PMC: 3119530. DOI: 10.1056/NEJMoa1007374. View

10.

Martin D, Maguire M, Ying G, Grunwald J, Fine S, Jaffe G . Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364(20):1897-908. PMC: 3157322. DOI: 10.1056/NEJMoa1102673. View

11.

Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi M, Shi E . Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012; 15(2):171-85. PMC: 3338918. DOI: 10.1007/s10456-011-9249-6. View

12.

Stewart M, Rosenfeld P, Penha F, Wang F, Yehoshua Z, Bueno-Lopez E . Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012; 32(3):434-57. DOI: 10.1097/IAE.0B013E31822C290F. View

13.

Fierson W . Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013; 131(1):189-95. DOI: 10.1542/peds.2012-2996. View

14.

Blencowe H, Lawn J, Vazquez T, Fielder A, Gilbert C . Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013; 74 Suppl 1:35-49. PMC: 3873709. DOI: 10.1038/pr.2013.205. View

15.

Avery R, Castellarin A, Steinle N, Dhoot D, Pieramici D, See R . Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014; 98(12):1636-41. PMC: 4251300. DOI: 10.1136/bjophthalmol-2014-305252. View

16.

Hartnett M . Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity. Clin Perinatol. 2014; 41(4):925-43. PMC: 4254506. DOI: 10.1016/j.clp.2014.08.011. View

17.

Salman A, Said A . Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity. Ophthalmic Res. 2014; 53(1):15-20. DOI: 10.1159/000364809. View

18.

Zehetner C, Kralinger M, Modi Y, Waltl I, Ulmer H, Kirchmair R . Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmol. 2014; 93(2):e154-9. DOI: 10.1111/aos.12604. View

19.

Yetik H, Gunay M, Sirop S, Salihoglu Z . Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol. 2014; 253(10):1677-83. DOI: 10.1007/s00417-014-2867-0. View

20.

Zhou Y, Jiang Y, Bai Y, Wen J, Chen L . Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2015; 254(1):31-6. DOI: 10.1007/s00417-015-2996-0. View